Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652531 | 1.00 | CTSS (0.47) | CTSSKCNH2CSNK1DCTSLFFAR2 | |
| SCHEMBL2650955 | 0.88 | KCNH2 (0.61) | CTSSKCNH2CSNK1DCTSLFFAR2 | |
| SCHEMBL2650958 | 0.88 | KCNH2 (0.61) | CTSSKCNH2CSNK1DCTSLFFAR2 | |
| SCHEMBL2650463 | 0.82 | GCK (0.58) | CTSSKCNH2CTSLCTSK | |
| SCHEMBL2650640 | 0.81 | KCNH2 (0.50) | KCNH2FFAR2KCNQ2NPC1RAB9A | |
| SCHEMBL2650644 | 0.81 | KCNH2 (0.50) | KCNH2FFAR2KCNQ2NPC1RAB9A | |
| SCHEMBL2650408 | 0.81 | KCNH2 (0.49) | CTSSKCNH2CTSLNPC1TP53 | |
| SCHEMBL2658612 | 0.80 | NPC1 (0.55) | KCNH2FFAR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2650645 | 0.80 | MEN1 (0.54) | KCNH2CSNK1DFFAR2NPC1TP53 | |
| SCHEMBL2658611 | 0.80 | NPC1 (0.55) | KCNH2FFAR2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341774-B1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1341774-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | claimed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | claimed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | claimed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | claimed |
| EP-1341774-B1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1341774-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6545155-B2 | Useful for increasing insulin secretion in the treatment of type II diabetes | HOFFMANN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-6448399-B1 | 3-CYCLOALKYL- OR PROPYL-2-(3,4-DIHALOPHENYL)-N-QUINOLINYL-, QUINAZOLINYL-, OR QUINOXOLINYL-PROPIONAMIDE. | HOFFMANN-LA ROCHE INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441184-B1 | SUCH AS N-BENZOOXAZOL-2-YL-3-CYCLOPENTYL-2-(4-METHANESULFONYL -PHENYL)-PROPIONAMIDE FOR INCREASING INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CTSS 1218/4885KCNH2 2019/4885CSNK1D 1910/4885 |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | GCKR, GCK, GPR119 | CTSS 1218/4885KCNH2 2019/4885CSNK1D 1910/4885 |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CTSS 1218/4885KCNH2 2019/4885CSNK1D 1910/4885 |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CTSS 1218/4885KCNH2 2019/4885CSNK1D 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.